Crinetics Pharmaceuticals, Inc. financial statements
Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Crinetics Pharmaceuticals, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.59
2.05
2.43
1.19
0.07
1.08
4.74
4.01
1.04
7.7
Cost of revenue
0
0
1.08
Gross profit
4.01
1.04
6.62
Research and development
5.1
9.23
24.5
41.5
57
84.3
130
169
240
332
Selling, general and administrative
58.1
99.7
191
General and administrative
1.53
1.94
6.66
13.5
18
24.5
42.4
58.1
99.7
Operating expenses
6.63
11.2
31.1
55
75
109
173
227
340
Operating income
-6.04
-9.13
-28.7
-53.8
-75
-108
-168
-223
-339
-517
Interest expense
0.01
0.01
Interest income
0.04
0.03
1.75
3.46
0.99
0.16
4.32
13.4
41.4
52
Other non-operating income
0.03
-0.03
1.6
3.41
1.14
0.06
4.97
13.3
40.9
51.6
Pre-tax income
-6.02
-9.16
-27.1
-50.4
-73.8
-108
-164
-215
-298
-465
Income tax
0
0
0
0
0
0
0
0
0
0.18
Net income
-6.02
-9.16
-27.1
-50.4
-73.8
-108
-164
-215
-298
-465
EBITDA
-5.95
-9
-28.2
-52.9
-74
-107
-167
-222
-336
-513
EPS, basic
-5.96
-6.68
-2.23
-2.09
-2.42
-2.80
-3.15
-3.69
-3.69
-4.95
EPS, diluted
-5.96
-6.68
-2.23
-2.09
-2.42
-2.80
-3.15
-3.69
-3.69
-4.95
Shares, basic (weighted)
1.01
1.37
12.1
24.2
30.4
38.4
52
58.1
80.8
94.1
Shares, diluted (weighted)
1.01
1.37
12.1
24.2
30.4
38.4
52
58.1
80.8
94.1
Balance sheet
FY2016
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
12.2
14.2
45
40.3
93.1
201
32.7
54.9
265
102
Short-term investments
119
78.1
77.8
133
302
504
1,090
926
Receivables
0
0.59
Inventory
0
2.02
Other current assets
0.24
0.88
0.67
1.02
0.91
1.93
0.45
2.39
3.46
Total current assets
15.2
167
123
177
345
345
574
1,375
1,048
Property, plant and equipment
0.4
4.23
3.95
3.18
2.83
3.5
10.9
12.1
14.3
Lease right-of-use assets
2.51
2.23
1.89
1.49
46.5
43.5
40.5
Other non-current assets
0.03
0.08
0.04
0
0.04
2
2.83
Total assets
15.6
171
130
183
351
352
635
1,435
1,126
Accounts payable
0.4
1.46
5.5
5.59
3.42
6.88
6.55
5.85
22.6
Accrued liabilities
0.18
4.19
Deferred revenue
2.2
2.06
2.18
1.24
Total current liabilities
0.9
7.93
8.34
10.5
16
27.7
43.9
59.7
85.1
Lease liabilities
4.85
4.01
3.07
2.02
47.6
44.6
42.1
Other non-current liabilities
0
0.83
3.24
Total liabilities
0.92
11.2
13.2
14.5
19.1
35.8
96.2
110
134
Paid-in capital
1.24
204
211
337
608
759
1,192
2,276
2,408
Retained earnings
-16.3
-43.4
-93.8
-168
-275
-439
-654
-952
-1,417
Other comprehensive income
0.06
0.15
0.03
-0.38
-3.93
0.98
0.96
1.87
Shareholders' equity
-6.2
-15
160
117
169
332
316
539
1,325
992
Total equity
-6.2
-15
160
117
169
332
316
539
1,325
992
Total liabilities and equity
15.6
171
130
183
351
352
635
1,435
1,126
Shares outstanding
1.55
0.02
24.3
33
47.6
53.9
68.2
92.9
95.6
Cash flow statement
FY2016
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-6.02
-9.16
-27.1
-50.4
-73.8
-108
-164
-215
-298
-465
Depreciation and amortization
0.09
0.13
0.47
0.89
0.95
0.92
0.98
1.1
2.8
3.9
Stock-based compensation
0.27
0.27
2.32
6.29
10.4
17.4
28.3
40.9
69.4
91
Deferred income tax
0
0
0
Change in receivables
0
0
-0.59
Change in inventory
0
0
-2.02
Change in payables
0.3
0.05
7.36
0.7
2.72
6.29
11
12.4
13.3
29
Cash from operations
-5.47
-9.48
-19.5
-46.4
-62
-88.6
-115
-169
-230
-378
Capital expenditures
-0.19
-0.3
-1.06
-0.49
-0.19
-0.44
-1.66
-4.69
-3.84
-5.76
Purchases of investments
-118
-108
-136
-125
-330
-528
-1,147
-1,004
Cash from investing
-0.19
-0.3
-119
41.7
0.22
-56.5
-174
-200
-575
174
Stock issued
0.07
106
0.13
114
250
117
370
985
0
Cash from financing
-0.05
11.8
170
0.07
115
253
122
391
1,015
40.6
Net change in cash
-5.71
2.04
31.3
-4.65
52.8
108
-167
22.2
210
-163
Free cash flow
-5.66
-9.78
-20.5
-46.9
-62.2
-89
-117
-173
-234
-384
Interest paid
0.01
0.01
Income taxes paid
0
0
0.09
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $84.95 on August 31, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-1,303.0%
Operating income / revenue.
EBITDA margin
-1,292.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-1,190.0%
Net income / revenue.
FCF margin
-1,009.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-1,002.0%
Cash from operations / revenue.
Return on equity (ROE)
-42.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-37.9%
Net income / average total assets.
Return on invested capital (ROIC)
-38.2%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
890.6%
Research and development expense / revenue.
Stock-based pay / revenue
234.8%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
6.3%
Capital expenditures / revenue.
D&A / revenue
10.1%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
640.7%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
17.6%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
155.3%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
537.2%
Gross profit vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-25.1%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
46.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
42.5%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-21.5%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
47.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
43.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
16.4%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
21.9%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
25.3%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
15.6x
Current assets / current liabilities.
Quick ratio
15.2x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
15.1x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.40
Revenue / diluted weighted shares.
FCF per share
-$4.03
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$4.00
Cash from operations / diluted weighted shares.
Book value per share
$11.27
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
214x
Market cap / revenue.
P/B
7.56x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
7.56x
Market cap / tangible book value, when positive.
EV/Sales
185x
Enterprise value / revenue.
FCF yield
-4.7%
Free cash flow / market cap.
Earnings yield
-5.6%
Net income / market cap (the inverse of P/E).
What was Crinetics Pharmaceuticals, Inc.'s revenue in fiscal 2025?
Crinetics Pharmaceuticals, Inc. reported revenue of $7.7M for fiscal 2025, 640.7% higher than the year before.
Was Crinetics Pharmaceuticals, Inc. profitable in fiscal 2025?
No. It reported a net loss of $465.3M.
How much free cash flow did Crinetics Pharmaceuticals, Inc. generate in fiscal 2025?
Cash from operations of $377.9M minus capital expenditures of $5.8M left free cash flow of -$383.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.